Here is the design of a clinical trial:

Official Title: Safety and Efficacy of Honeycomb Microporous Covered Stents (NCVC-CS1) for the Treatment of Intracranial Aneurysms: a Multicenter, Uncontrolled, Exploratory Trial

Included conditions:
- Intracranial Aneurysm

Study Armgroups:
- {'label': 'Treatment group', 'type': 'EXPERIMENTAL', 'description': 'neuroendovascular therapy(NCVC-CS1)', 'interventionNames': ['Device: NCVC-CS1']}

Interventions:
- {'type': 'DEVICE', 'name': 'NCVC-CS1', 'description': 'Intervention Description', 'armGroupLabels': ['Treatment group']}

Primary Outcomes:
- {'measure': 'Safety evaluation: Any stroke or death related to the procedure within 180 days', 'timeFrame': '180 days after the procedure'}
- {'measure': 'Efficacy evaluation: Complete obliteration of target aneurysm and patency of target vessel (less than 50% stenosis) confirmed by angiography at 180 days after the procedure', 'timeFrame': '180 days after the procedure'}

Please estimate the sample size based on the assumption: 
two-sided 95% exact (Clopper-Pearson type) CI with a width equal to 44.2%
Sample size
        The planned subject number in this study is 12. The sample size was calculated based on the primary efficacy endpoint. A sample size of 10 would provide a two-sided 95% exact (Clopper-Pearson type) CI with a width equal to 44.2% (55.5% to 99.7%), assuming 90% complete obliteration of the target aneurysm and patency of the target vessel (PASS V.11; NCSS, Kaysville, UT, USA). A total of 12 patients will be recruited into the study, accounting for withdrawals from the study.